- $46.16m
- -$41.88m
- $0.10m
Brief: Ibio Reports Fiscal Year 2026 Financial Results And Provides Corporate Update
Brief: Ibio Reports Q3 Fiscal Year 2026 Financial Results And Provides Corporate Update
U.S. STOCKS ON THE MOVE-Meta, Legence, Chegg
U.S. STOCKS ON THE MOVE-Hims & Hers, Chewy, Longeveron
iBio rises as obesity drug gets nod for human trial in Australia
U.S. STOCKS ON THE MOVE-Delta, Levi's, banks
Brief: IBio Received Regulatory Clearance To Initiate Its Phase 1 Clinical Trial Of Ibio-600 In Australia
U.S. STOCKS ON THE MOVE-Delta, GATX, Humana
iBio rises as obesity drug gets first green light for human trial in Australia
Brief: IBio To Provide An Update On Cardiopulmonary Program Targeting Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction (Ph-Hfpef)
Brief: iBio Enters Open Market Sale Agreement With Jefferies
Brief: iBio Inc Files For Mixed Shelf Of Upto $200 Million
NASDAQ RESUMED AT 09:43 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:38 AM
U.S. RESEARCH ROUNDUP-Block, Morgan Stanley, W R Berkley
Brief: iBio Announces Proposed Public Offering
Brief: Ibio And Astralbio Unveil Obesity Program With Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results
Brief: IBio Initiates Non-Human Primate Study Of First-In-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention In Weight Regain After GLP-1 Treatment
Brief: iBio Reports Fiscal Third Quarter 2025 Financial Results